Q1 Earnings Estimate for Prenetics Global Issued By Sidoti

Prenetics Global Limited (NASDAQ:PRE) – Stock analysts at Sidoti lowered their Q1 2026 EPS estimates for Prenetics Global in a research report issued on Monday, March 30th. Sidoti analyst A. Hantman now expects that the company will earn ($0.77) per share for the quarter, down from their previous estimate of ($0.74). The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share. Sidoti also issued estimates for Prenetics Global’s Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($1.09) EPS, FY2026 earnings at ($3.55) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at $0.88 EPS, Q4 2027 earnings at $1.45 EPS and FY2027 earnings at $2.16 EPS.

Prenetics Global (NASDAQ:PRE) last issued its quarterly earnings data on Wednesday, February 18th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.22. The firm had revenue of $36.60 million for the quarter, compared to the consensus estimate of $36.15 million. Prenetics Global had a negative net margin of 61.33% and a negative return on equity of 19.07%.

Other equities analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a report on Thursday, January 22nd. Lake Street Capital started coverage on Prenetics Global in a research report on Monday, March 16th. They issued a “buy” rating and a $29.00 price objective for the company. Wall Street Zen downgraded Prenetics Global from a “buy” rating to a “hold” rating in a research note on Monday, February 16th. Finally, Roth Mkm started coverage on Prenetics Global in a research report on Wednesday, February 11th. They set a “buy” rating and a $36.00 target price on the stock. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.33.

Prenetics Global Stock Up 1.3%

NASDAQ:PRE opened at $19.57 on Wednesday. The stock has a market capitalization of $329.36 million, a price-to-earnings ratio of -4.87 and a beta of 0.27. Prenetics Global has a 52 week low of $3.09 and a 52 week high of $23.63. The firm has a 50 day moving average of $19.40 and a 200 day moving average of $16.20.

Prenetics Global declared that its Board of Directors has initiated a stock repurchase program on Friday, March 6th that permits the company to repurchase $40.00 million in shares. This repurchase authorization permits the company to repurchase up to 15.8% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in shares of Prenetics Global during the fourth quarter worth $1,302,000. 683 Capital Management LLC acquired a new position in shares of Prenetics Global in the 4th quarter valued at $1,181,000. Aberdeen Group plc acquired a new position in shares of Prenetics Global in the 3rd quarter valued at $979,000. Millennium Management LLC purchased a new position in Prenetics Global in the 4th quarter worth $810,000. Finally, Marshall Wace LLP acquired a new stake in Prenetics Global during the 4th quarter worth about $788,000. Institutional investors and hedge funds own 25.01% of the company’s stock.

More Prenetics Global News

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: Sidoti sharply raised its FY2027 outlook to a profitable $2.16 EPS (from $1.65), and boosted Q3 and Q4 2027 estimates (Q3 to $0.88, Q4 to $1.45), signaling a modeled transition to earnings growth in 2027 — this drives a more bullish medium‑term valuation case. Sidoti estimate changes
• Positive Sentiment: Sidoti also raised its Q4 2026 estimate (to -$1.09 from -$1.19) and nudged FY2026 slightly less negative, suggesting analysts see improving margins later in the year — a constructive sign for consensus revision momentum. Sidoti estimate changes
• Positive Sentiment: Prenetics announced a strategic partnership with Superpower to combine clinical‑grade supplements and blood diagnostics, which could expand consumer revenue streams and strengthen recurring test + product bundles if commercial adoption follows. Prenetics partners with Superpower
• Neutral Sentiment: Sidoti’s FY2026 estimate was adjusted slightly (to -$3.55 from -$3.56) — an immaterial change that leaves near‑term cash‑flow and loss expectations largely intact. Sidoti estimate changes
• Negative Sentiment: However, Sidoti trimmed several near‑term 2026 quarter estimates (Q1–Q3 2026 and Q2 2026 in particular were nudged lower), indicating softer near‑term profitability and execution risk that could pressure short‑term stock performance if results miss. Sidoti estimate changes
• Negative Sentiment: Sidoti also slightly reduced Q2 2027 (to -$0.05) and cut some 2026 quarterly forecasts — these downward tweaks temper the pace of expected improvement and are a reminder earnings recovery is projected to be back‑loaded. Sidoti estimate changes

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.